Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study
| Autor: | Mohamad Nikpouraghdam, Mohammad Rezapour, Abbas Ali Imani Fooladi, Payam Tabarsi, Elham Askari, Ali Bahramifar, Ramezan Jafari, Sina Imanizadeh, Abdol Majid Cheraghali, Jafar Aslani, Samira Shahverdi, Nariman Sadri, Ehsan Sharifipour, Farzaneh Bolouki Moghaddam, Shanaz Sali, Mohammad Hossein Jarahzadeh, Mohammad Hossein Ranjkesh, Mahmood Salesi, Mokhtar Tazik, Peyman Eshghi, Mohammad Hosseini, Nematollah Joneidi Jafari, Nastaran Khodakarim, Hassan Abolghasemi, Matin Moeini Maleki, Shamsi Okati, Behzad Einollahi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Convalescent plasma Coronavirus disease 2019 (COVID-19) Cost effectiveness medicine.medical_treatment 030204 cardiovascular system & hematology Article 03 medical and health sciences Young Adult 0302 clinical medicine Pharmacotherapy Internal medicine medicine Intubation Humans Clinical efficacy COVID-19 Serotherapy Aged Aged 80 and over Hospital stay business.industry SARS-CoV-2 Mortality rate Immunization Passive COVID-19 Hematology Middle Aged Clinical trial Treatment Outcome Female business 030215 immunology |
| Zdroj: | Transfusion and Apheresis Science |
| ISSN: | 1473-0502 |
| Popis: | Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients' need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect